Abstract
This chapter describes the possibility of using peptide receptor radionuclide therapy (PRRT) as neoadjuvant treatment. PRRT is acknowledged to be a palliative treatment. Recently it has been reported that tumor size decrease followed by surgical intervention might be achieved in patients with neuroendocrine tumors (NETs) treated with somatostatin analogs labeled with beta emitters. Such outcome of therapy has been described in a relatively small group of patients. In those patients, the treatment enabled total or partial excision of the tumor, also with liver metastases. Reduction of tumor dimensions or total excision of the tumor corresponded with prolongation of overall survival. The discussed papers on this subject differ in details of treatment (utilization of various isotopes, total activity of the isotope, or combination with radiosensitizing chemotherapy). The chapter presents a brief review of recently published manuscripts.
Keywords
- Liver Metastasis
- Peptide Receptor Radionuclide Therapy
- Pancreatic Tail
- Pancreatic Neuroendocrine Tumor
- Decrease Tumor Size
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsAbbreviations
- CT:
-
Computed tomography
- Ki index:
-
Proliferation index
- NET:
-
Neuroendocrine tumor
- PET/CT:
-
Positron emission tomography/computed tomography
- PNT:
-
Pancreatic neuroendocrine tumor
- PRRT:
-
Peptide receptor radionuclide therapy
- RECIST:
-
Response evaluation criteria for solid tumors
- SPECT-CT:
-
Single-photon emission computed tomography
- T1/2 :
-
Physical half-life
- 5FU:
-
5-Fluorouracil
References
Barber TW, Hofman MS, Thomson BN et al (2012) The potential for induction peptide receptor chemoradionuclide therapy to render inoperable pancreatic and duodenal neuroendocrine tumors resectable. Eur J Surg Oncol 38:64–71
Cremonesi M, Ferrari M, Bodei L et al (2006) Dosimetry in peptide radionuclide receptor therapy: a review. J Nucl Med 47:467–1475
Faiss S, Pape UF, Bohming M et al (2003) Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors - the international lanreotide and interferon alfa study group. J Clin Oncol 21:2689–2696
Kaemmerer D, Prasad V, Daffner W et al (2009) Neoadjuvant peptide receptor radionuclide therapy for an inoperable neuroendocrine pancreatic tumor. World J Gastroenterol 15:5867–5870
Kazanjian KK, Reber HA, Hines OJ (2006) Resection of pancreatic neuroendocrine tumors: results of 70 cases. Arch Surg 141:765–769
Nomura N, Fujii T, Kanazumi N et al (2009) Nonfunctioning neuroendocrine pancreatic tumors: our experience and management. J Hepatobiliary Pancreat Surgery 16:639–647
Oberg K, Kvols L, Caplin M et al (2004) Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system. Ann Oncol 15:966–973
Rinke A, Muller HH, Schade- Brittinger C et al (2009) Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumor: a report from the PROMID study group. J Clin Oncol 27:4656–4663
Sowa-Staszczak A, Pach D, Chrzan R et al (2011) Peptide receptor radionuclide therapy as a potential tool for neoadjuvant therapy in patients with inoperable neuroendocrine tumors (NETs). Eur J Nucl Med Mol Imaging 38:1669–1674
Stoeltzing O, Loss M, Huber M et al (2010) Staged surgery with neoadjuvant 90Y-DOTATOC therapy for down-sizing synchronous bilobular hepatic metastases from a neuroendocrine pancreatic tumor. Langenbecks Arch Surg 395:185–192
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Sowa-Staszczak, A., Hubalewska-Dydejczyk, A., Tomaszuk, M. (2013). PRRT as Neoadjuvant Treatment in NET. In: Baum, R., Rösch, F. (eds) Theranostics, Gallium-68, and Other Radionuclides. Recent Results in Cancer Research, vol 194. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-27994-2_27
Download citation
DOI: https://doi.org/10.1007/978-3-642-27994-2_27
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-27993-5
Online ISBN: 978-3-642-27994-2
eBook Packages: MedicineMedicine (R0)